🔥 Ad:Click Here for Exclusive!

Leronlimab

Introduction to Leronlimab

Leronlimab (PRO 140) is a humanized IgG4 monoclonal antibody developed by CytoDyn Inc. It is an investigational drug that targets the C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune cells. While not yet approved by regulatory agencies, leronlimab has shown potential in various therapeutic areas, most notably in HIV treatment and certain cancers.

Key points:

  • Humanized monoclonal antibody targeting CCR5
  • Investigational drug with potential applications in HIV, cancer, and inflammatory conditions
  • Administered via subcutaneous injection
  • Currently in various stages of clinical trials for multiple indications

Mechanism of Action

Leronlimab's mechanism of action primarily involves its interaction with the CCR5 receptor:

  1. CCR5 Binding: Leronlimab specifically binds to CCR5 on the surface of immune cells, particularly T cells.
  2. HIV Entry Inhibition: In the context of HIV treatment, this binding blocks the interaction between CCR5 and the HIV envelope glycoprotein gp120, preventing viral entry into host cells.
  3. Immunomodulation: CCR5 blockade can also modulate immune cell trafficking and function, which may have implications for cancer and inflammatory conditions.

Important characteristics:

  • Does not cause CCR5 internalization, unlike small molecule CCR5 antagonists
  • May preserve normal immune function better than other CCR5 blockers
  • Long half-life allows for less frequent dosing compared to daily oral medications
  • Potential for synergistic effects when combined with other antiretroviral drugs in HIV treatment

Potential Indications

While leronlimab is still investigational, it has been studied for several potential indications:

  1. HIV Treatment:
    • As a component of antiretroviral therapy in treatment-experienced patients
    • Potential for monotherapy in virally suppressed patients (maintenance therapy)
  2. HIV Pre-Exposure Prophylaxis (PrEP):
    • Long-acting injectable option for HIV prevention
  3. Cancer:
    • Metastatic triple-negative breast cancer
    • Other solid tumors where CCR5 plays a role in metastasis
  4. COVID-19:
    • Potential immunomodulatory effects in severe COVID-19
  5. Inflammatory Conditions:
    • Non-alcoholic steatohepatitis (NASH)
    • Other inflammatory conditions where CCR5 is implicated

Clinical Pharmacology

Pharmacokinetics:

  • Administration: Subcutaneous injection
  • Absorption: Bioavailability estimated to be over 80% after subcutaneous administration
  • Distribution: Limited information available on tissue distribution
  • Metabolism: As a monoclonal antibody, it is expected to be catabolized into peptides and amino acids
  • Elimination: Estimated half-life of 10-14 days

Pharmacodynamics:

  • Dose-dependent CCR5 receptor occupancy observed in clinical studies
  • Rapid and sustained antiviral effect in HIV-1 infected patients
  • No evidence of viral resistance development in long-term studies

Clinical Trials

HIV Treatment:

  • Phase IIb/III (CD02): Evaluated leronlimab as a switch regimen in virologically suppressed patients
    • Results: Demonstrated non-inferiority to standard antiretroviral therapy at 48 weeks
  • Phase III (CD03): Investigated leronlimab in combination with optimized background therapy in treatment-experienced patients
    • Results: Showed significant viral load reduction and increased CD4 T cell counts

Cancer:

  • Phase Ib/II: Evaluated leronlimab in metastatic triple-negative breast cancer
    • Results: Showed potential in reducing circulating tumor cells and improving overall survival

COVID-19:

  • Phase II (CD10): Mild-to-moderate COVID-19
    • Results: Did not meet primary endpoint, but showed potential benefits in certain subgroups
  • Phase III (CD12): Severe-to-critical COVID-19
    • Results: Did not meet primary endpoints, but suggested potential benefit in critically ill subgroup

Adverse Effects

Based on available clinical trial data, leronlimab has generally been well-tolerated. Reported adverse effects include:

  • Injection site reactions (most common)
  • Headache
  • Nausea
  • Fatigue
  • Diarrhea

Notable safety observations:

  • No significant changes in liver function tests or lipid profiles observed in long-term studies
  • No evidence of increased susceptibility to infections, including those typically associated with CCR5 deficiency
  • Low incidence of anti-drug antibodies in clinical trials

It's important to note that as an investigational drug, the full safety profile of leronlimab is still being characterized through ongoing clinical trials and long-term follow-up studies.

Drug Interactions

As leronlimab is still investigational, comprehensive drug interaction studies have not been conducted. However, based on its mechanism of action and nature as a monoclonal antibody, some predictions can be made:

  • Low likelihood of interactions with drugs metabolized by cytochrome P450 enzymes
  • Potential for additive or synergistic effects when combined with other CCR5 antagonists
  • May alter the pharmacodynamics of drugs that rely on CCR5-mediated effects

Considerations for HIV treatment:

  • No significant interactions observed when used in combination with various antiretroviral drugs in clinical trials
  • Potential for enhanced efficacy when combined with other classes of antiretroviral drugs

Further studies are needed to fully characterize the drug interaction profile of leronlimab, particularly if it advances to regulatory approval for various indications.

Special Populations

As an investigational drug, data on leronlimab use in special populations is limited. However, some considerations based on available information include:

Pregnancy and Lactation:

  • No human data available on use during pregnancy or lactation
  • Animal studies have not shown evidence of harm to the fetus
  • As an IgG antibody, leronlimab is expected to cross the placenta and be excreted in breast milk

Pediatric Use:

  • Safety and efficacy in pediatric patients have not been established
  • Potential for future studies in pediatric HIV patients

Geriatric Use:

  • Limited data available on use in elderly patients
  • No specific age-related concerns identified in available studies

Renal and Hepatic Impairment:

  • No specific studies conducted in patients with renal or hepatic impairment
  • As a monoclonal antibody, significant impact of renal or hepatic function on pharmacokinetics is not expected

Future Prospects

Leronlimab's unique mechanism and potential applications in multiple therapeutic areas present several opportunities for future development:

  1. HIV Treatment:
    • Potential as a long-acting maintenance therapy, reducing pill burden
    • Possible role in multidrug-resistant HIV
  2. HIV Prevention:
    • Development as a long-acting injectable PrEP option
  3. Oncology:
    • Further exploration in metastatic cancers, particularly where CCR5 is implicated
    • Potential combination therapies with immune checkpoint inhibitors
  4. Autoimmune and Inflammatory Diseases:
    • Investigation in conditions like NASH, multiple sclerosis, or rheumatoid arthritis
  5. COVID-19 and Other Viral Infections:
    • Continued evaluation of its potential in severe viral infections

Future research may also focus on:

  • Optimizing dosing regimens for different indications
  • Developing subcutaneous self-administration formulations
  • Exploring combination therapies in various disease settings

Regulatory Status

As of 2023, leronlimab has not received regulatory approval for any indication. Its current regulatory status includes:

  • FDA:
    • Fast Track designation for HIV combination therapy
    • Fast Track designation for HIV monotherapy
    • Fast Track designation for metastatic triple-negative breast cancer
  • Clinical Trials:
    • Ongoing Phase III trials in HIV
    • Phase II trials in oncology
    • Completed trials in COVID-19

Challenges and Controversies:

  • FDA has issued several communications regarding concerns about some of the company's public statements and data presentations
  • Delays in submitting Biologics License Application (BLA) for HIV indication
  • Ongoing discussions with regulatory agencies about trial designs and endpoints

The path to potential approval will likely require additional clinical data and rigorous evaluation by regulatory authorities. Healthcare providers and researchers should stay updated on the latest regulatory developments regarding leronlimab.



Further Reading
Tags:

Powered by Blogger.